Bayer’s June Gauntlet: A Supreme Court Verdict, a Glaucoma Deal, and a New CFO Takes Charge

Bayer stock surged 45% in 2026 but faces key tests: Supreme Court glyphosate ruling, $2.45B Perfuse acquisition, and CFO transition with €5B litigation payouts.

Bayer’s stock has staged a remarkable recovery in 2026, gaining roughly 45% so far this year. But the next two weeks will test whether that rally has legs — or whether legal and financial crosswinds will knock it back. After closing at €38.56 on Tuesday, the shares added 1.25% on Wednesday to reach €38.98, a sign that investors are cautiously optimistic as the company juggles a once-in-a-decade Supreme Court ruling, an ambitious ophthalmology acquisition, and a change in its finance leadership.

The most immediate catalyst is a corporate move designed to shore up Bayer’s pharmaceuticals pipeline. The group has completed its takeover of US biotech firm Perfuse Therapeutics, paying an upfront $300 million. If all development milestones are met, the total consideration could reach $2.45 billion. The deal’s centrepiece is PER-001, an implant for glaucoma that is currently in Phase II trials. The device releases its active ingredient over six months, a clear advantage over daily eye drops and a potential challenger to Bayer’s existing blockbuster Eylea, which faces growing competition. Analysts see the transaction as a necessary step to refresh the product portfolio.

Yet the biggest swing factor for the share price remains in the courtroom, not the lab. In the last week of June, the US Supreme Court is expected to deliver its verdict in the “Durnell” case. The central question is whether federal law — specifically, the EPA’s nationwide approval of glyphosate — overrides state-level warning requirements. If the court answers yes, future floodgates of litigation could be effectively closed. If no, Bayer will remain exposed to a constant stream of new claims, no matter how many settlements it brokers. A federal judge in Missouri has already allowed a $7.25 billion class-action settlement to proceed toward final approval, with a hearing set for 9 July 2026. But even that deal does not remove the existential threat the Supreme Court ruling addresses.

Separately, the company is navigating a leadership transition. Dr. Judith Hartmann, formerly of Bertelsmann, took over as chief financial officer in early June. She steps into a role where cash flow management is paramount. In 2026, Bayer expects around €5 billion in litigation-related payouts. The free cash flow is forecast to turn as negative as €2.5 billion, pushing net financial debt — already near €30 billion at the end of 2025 — higher. Hartmann’s task is to convert operational improvements into a healthier balance sheet, a challenge she will address in depth when Bayer reports second-quarter earnings on 4 August.

Optimists argue that a favourable Supreme Court decision would be a genuine turning point. Combined with the eventual Missouri settlement approval, it could allow the company to largely put the glyphosate saga behind it. On the operational side, regulators in Europe and the US are reviewing Asundexian, a stroke prevention drug that cut stroke risk by 26% in a Phase III trial. Meanwhile, the FDA granted approval to the contrast agent AMBELVIST in mid-June. If legal clarity arrives, the stock — currently trading about 2% above its 50-day moving average — could set its sights on the 52-week high of €49.93.

The bear case is equally stark. A negative Supreme Court ruling would leave Bayer vulnerable to recurring legal costs and keep the debt overhang firmly in focus. The debt-reduction strategy would be undermined by constant cash outflows, and shares could slip back toward the yearly low of €25.09. Although the relative strength index of 59.6 suggests the stock is not yet overbought, much of the recent rally has been built on hopes of a legal resolution. A disappointment would hit hard.

For now, the market is watching three dates closely: any day in the last week of June for the Supreme Court ruling, 9 July for the final fairness hearing in Missouri, and 4 August for the quarterly update that will show whether Hartmann can put numbers behind the rhetoric. How those events unfold will decide whether Bayer’s June is remembered as a turning point or a false dawn.